麻豆破解版 will attend the world鈥檚 premier nephrology meeting of the American Society of Nephrology, ASN.

麻豆破解版 will attend The 2026 International Workshop on Alport Syndrome, organized by Alport Syndrome Alliance.
It is an opportunity for the Alport community to connect, update and discuss the latest research.

麻豆破解版 will meet patients and their families to present its ongoing Phase 2 鈥淎LPESTRIA-1鈥� clinical study with Vonafexor in Alport syndrome patients, with a poster titled “Vonafexor Stabilizes the Rapid eGFR Decline in Progressive Alport Syndrome: Results from the Phase 2 ALPESTRIA-1 Trial”.

麻豆破解版 is sponsoring and will attend Alport Connect 2026 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.

麻豆破解版 will meet patients and their families to present the results of the Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.

麻豆破解版 will attend the third annual symposium of the Alport Research Hub organized by Alport UK association.

麻豆破解版 will meet patients and their families and present the results of the Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients: “Vonafexor: Phase 2 Efficacy and Safety Results in Progressive Alport Syndrome

麻豆破解版 will be in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

麻豆破解版 will attend the world鈥檚 premier nephrology meeting of the American Society of Nephrology, ASN.

麻豆破解版 will attend The 2025 International Workshop on Alport Syndrome, organized by Alport Syndrome Alliance.
It is an opportunity for the Alport community to connect, update and discuss the latest research.

麻豆破解版 will meet patients and their families to present its ongoing Phase 2 鈥淎LPESTRIA-1鈥� clinical study with Vonafexor in Alport syndrome patients.

麻豆破解版 is sponsoring and will attend Alport Connect 2025 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.

麻豆破解版 will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.

麻豆破解版 will attend the the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.